Name

Curaleaf Laboratories

Legal name

Rokshaw Ltd

Website

https://curaleaflaboratories.co.uk

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Sunderland

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Cannabis Product Manufacturing & Distribution: Manufacture and distribution of EU-GMP medical cannabis products to specialist clinics, pharmacies, and healthcare professionals across the UK. Products include dried flowers, oils, pastilles, vape cartridges, suppositories, pessaries, and inhalation devices. B2B revenue model supplying prescription medicines to the growing UK medical cannabis market.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Curaleaf Laboratories manufactures and distributes EU-GMP cannabis-based medicinal products (CBPMs) at its MHRA-approved facility in Sunderland, UK. The product portfolio includes dried flowers, oils, pastilles, liquid vape cartridges, suppositories, pessaries, and the proprietary Curaleaf Que Medical Inhalation Device (QMID). Products are sold wholesale to specialist clinics, community pharmacies, and healthcare professionals under B2B partnership schemes including the Prescribing Programme, Pharmacy Partnership Scheme, and Manufacturing and Distribution Service.

Product overview

Curaleaf Laboratories is a UK-based manufacturer and distributor of EU-GMP medical cannabis products, operating as part of Curaleaf International (subsidiary of Curaleaf Holdings). The company offers a portfolio of pharmaceutical-grade medical cannabis products including Dried Flowers, Oils, Pastilles, Liquid Vape Cartridges, Suppositories, and Pessaries. Their flagship innovation is the Curaleaf Que Medical Inhalation Device (QMID) - the first CE-certified liquid inhaler for cannabis-based medicines. The company provides manufacturer and distribution services for producers (Manufacturing and Distribution Service), prescribers (Curaleaf Prescribing Programme), and pharmacies (Pharmacy Partnership Scheme), alongside their own clinical (Curaleaf Clinic) and pharmacy (Curaleaf Pharmacy) operations. The vertically integrated supply chain spans cultivation at Terra Verde in Portugal, extraction at Medalchemy in Spain, and UK-based manufacturing at their Sunderland facility.

Differentiator

Problem solved

Functional benefit

Products and services

• Dried Flowers EU-GMP medical cannabis dried flower products manufactured for prescription use by specialist doctors and clinics across the UK. Part of the core Curaleaf range of UK-manufactured medical cannabis products.
• Oils Full spectrum medical cannabis oils manufactured to EU-GMP standards, providing consistent dosing for patients prescribed cannabis-based medicinal products by specialist UK clinicians.
• Pastilles Medical cannabis pastilles — a novel oral dosage form pioneered by Curaleaf Laboratories as an alternative to oils and dried flowers for prescribed patients.
• Liquid Vape Cartridges Liquid vape cartridges for inhalation delivery of medical cannabis, available in 0.5mL and 1.0mL sizes for use with the QMID inhaler device. Part of the comprehensive EU-GMP product range.
• Medical Cannabis Suppositories and Pessaries Pioneering medical cannabis suppositories and pessaries — first licensed UK-manufactured dosage forms of this type, designed for specialist prescribers treating patients who may not benefit from traditional administration methods.
• Curaleaf Que Medical Inhalation Device (QMID) CE-certified EU Class IIa liquid inhaler device for precise, standardized timed dosing of cannabis-based medicines. Features inhalation activation, reusable hardware, and replaceable 0.5mL and 1.0mL cartridges. First certified liquid medical cannabis inhaler in the UK.
• Manufacturing and Distribution Service B2B contract manufacturing and distribution service for medical cannabis producers seeking to enter or expand in the UK market. Provides MHRA-approved manufacturing, quality assurance, and established UK distribution under partner brands or Curaleaf-owned ranges.
• Curaleaf Formulary Comprehensive product formulary for healthcare professionals covering the widest variety of EU-GMP UK-manufactured medical cannabis formulations and dosage forms, providing specialist prescribers with a single trusted source for prescribing decisions.

Quantifiable outcome

• 99% next-day delivery rate for wholesale and pharmacy customers (orders before 2:30pm)
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, strategic and minor.

• Herdade das Barrocas (HDB)coreStrategic or Co-development Partner · 22 June 2026Strategic partnership to reintroduce HDB products to the UK medical cannabis market. Combines Herdade das Barrocas' cultivation capabilities in Portugal with Curaleaf Laboratories' MHRA-approved manufacturing, quality assurance and distribution infrastructure. Cannabis flower cultivated by HDB supplied to Curaleaf for UK manufacturing, packaging and distribution. Initial product availability expected from June 2026.
• Sanity GroupcoreStrategic or Co-development Partner · 26 February 2026Partnership to develop, manufacture, and commercialize innovative medical cannabis products tailored to UK patients and healthcare professionals. Curaleaf leverages MHRA-approved infrastructure and compliance framework while Sanity Group contributes pharmaceutical know-how, intellectual property and experience in cannabinoid-based therapeutics. First products expected available from Q1 2026.
• Australian Natural Therapeutics Group (ANTG)coreStrategic or Co-development Partner · 12 November 2025Partnership to manufacture and distribute ANTG's range of pharmaceutical-grade medicinal cannabis products across the UK. Combines Curaleaf's state-of-the-art UK manufacturing capabilities and established distribution network with ANTG's expertise in cultivating and developing consistent cannabis formulations. First products available on prescription from November 2025.
• Jupiter Research LLC (TILT Holdings)strategicTechnology or Integration · 1 September 2025Developed the Curaleaf Que Medical Inhalation Device (QMID) in partnership with Jupiter Research. Jupiter's intellectual property and device development expertise combined with Curaleaf's pharmaceutical manufacturing capabilities to create first CE-certified liquid inhaler for cannabis-based medicines.
• Dalgety LtdcoreStrategic or Co-development Partner · 1 January 2024Partnership to exclusively manufacture and distribute medical cannabis API from Dalgety's UK cultivation facility. Dalgety is the first domestic cultivator with EU-GMP licenses for cultivation and supply of medical cannabis products. Full UK vertical supply chain from cultivation to distribution while maintaining EU-GMP standards. Dalgety's 30,000+ sq ft indoor facility features AI-controlled environmental management and precision hydroponic cultivation.
• Medical Cannabis Clinicians Society (MCCS)coreGTM or Marketing Partner · 1 January 2024Gold education partner providing CPD-accredited cannabis education to healthcare professionals. Delivers educational content, webinars, surveys, roundtables and clinical resources. Supports recruitment and education of new prescribers entering the medical cannabis space.
• Terra Verde (Portugal)coreStrategic or Co-development Partner · 1 January 2019Part of Curaleaf International vertical supply chain. Terra Verde holds the second oldest cultivation licence in Europe with 2.8 hectares of indoor greenhouse cultivation. Pioneer in plant-based research, genetics and production of consistent, natural and high-quality medicinal cannabis.
• Medalchemy (Spain)coreStrategic or Co-development Partner · 1 January 2019Part of Curaleaf International vertical supply chain. Medalchemy is a leading research laboratory and manufacturing facility in Spain, GMP certified since 2013 with a decade of experience in research, development and manufacture of active pharmaceutical ingredients (APIs). First laboratory in Spain to receive a licence to manufacture and export cannabis oils.
• Sunderland CollegeminorOthersEducational partnership supporting creation of highly skilled scientific and pharmaceutical jobs in the North East of England while raising awareness of medical cannabis as a growing healthcare sector.
• University of SunderlandminorOthersEducational partnership supporting skills development and awareness of medical cannabis as a rapidly growing healthcare sector in the UK.
• Curaleaf InternationalcoreOthersCuraleaf Laboratories is part of Curaleaf International, which is a subsidiary of Curaleaf Holdings Inc., the largest cannabis company in the world. Provides access to global supply and distribution partnerships throughout Europe and the UK.

Scale indicators4 records

Recent moves8 records

Broad incumbents

• Aurora Cannabis: Large international medical and recreational cannabis producer with EU-GMP certified facilities; a broad incumbent whose EU-produced CBPMs compete with Curaleaf's UK-manufactured portfolio across European distribution.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Originator of Epidiolex and historically the dominant UK-based cannabis-derived pharmaceutical company; now part of Jazz Pharmaceuticals. A broad incumbent whose cannabinoid pharma capabilities and UK regulatory heritage inform the benchmark Curaleaf operates against.
• Tilray Brands: Global cannabis incumbent with EU-GMP manufacturing footprint and existing UK medical cannabis imports — competes broadly with Curaleaf in the UK supply market and has the scale to challenge on price and product breadth.

Others

• Sativa Investments: UK-listed cannabis investment and operating platform covering cultivation, manufacturing, and clinic exposure; ecosystem participant and capital-markets vehicle relevant to the broader UK medical cannabis sector Curaleaf serves.

Direct peers

• Celadon Pharmaceuticals: UK-based MHRA-licensed medical cannabis cultivator and manufacturer focused on EU-GMP active pharmaceutical ingredients and finished CBPMs — directly competes with Curaleaf's Sunderland manufacturing and UK supply chain.
• Lyphe Group: UK medical cannabis operator spanning specialist clinics, pharmacy dispensing, and product supply through its proprietary formulary — overlaps with Curaleaf's Clinic, Pharmacy, and Prescribing Programme ecosystem.
• Grow Pharma: UK-based MHRA-licensed manufacturer and distributor of medical cannabis products, operating a vertically integrated model targeting specialist clinics and pharmacies — the closest direct competitor to Curaleaf Laboratories in the UK CBPM market.
• Kanabo: Israel- and UK-focused medical cannabis company with proprietary inhalation device technology (similar device-led differentiation to Curaleaf's QMID) and growing UK pharmacy distribution — directly comparable on product format and route-to-market.

Emerging players

• EMMAC Life Sciences: European medical cannabis operator with cultivation and manufacturing across multiple EU jurisdictions — an emerging player with overlapping EU-GMP supply that competes for UK distribution partnerships and producer-to-UK pathways.
• Khiron Life Sciences: Vertically integrated medical cannabis company with EU operations and a clinical-services-led UK distribution approach — an emerging player with adjacent go-to-market overlap on clinics and patient access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curaleaf-laboratories

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curaleaf Laboratories